Work

Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia

Year: 2020

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Brain Imaging and Behavior

DOI: 10.1007/s11682-020-00375-7

Authors: Michael M. Francis, Tom A. Hummer, Emily Liffick, Jenifer L. Vohs, Nikki F. Mehdiyoun, Andrew C. Visco, Ziyi Yang, Richard J. Kovacs, Ying Zhang, Alan Breier

Institutions: Eskenazi Health, Indiana University School of Medicine, Indiana University – Purdue University Indianapolis, Indiana University Indianapolis, Indiana University

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Stanley Medical Research Institute

Award: SMRI Treatment Trial 11T-001: fingolomod for schizophrenia

OpenAlex ID: W3083549033

FWCI: 3.278

Cites: 93

Cited by: 18

Related to: 10